The pet medication manufacturers industry in the US focuses on providing medical solutions for pets, ranging from pharmaceuticals to supplements. Companies in this sector work on pet healthcare innovations, including treatments for common ailments to advanced therapies for chronic conditions, partly driven by increasing pet ownership. The market is evolving clearly, emphasizing sustainability and the health-conscious pet owner. As veterinary science progresses, manufacturers are expected to adopt cutting-edge technology like telehealth and personalized medications. Notably, the growing popularity of pet insurance is influencing consumer spending, indicating a promising trajectory for pet medication manufacturers in the foreseeable future.


The top investors in the pet medication sector showcase a blend of venture capital, private equity, and corporate financing. Operating from key locations like San Francisco, New York, and Boston, these investors range in size, with many managing portfolios that feature significant assets. Founded between 1946 and 2023, they have collectively executed over 1,000 deals in 2024, indicating a robust interest in pet healthcare funding. Their significant backing reflects an awareness of the increasing demand for veterinary services and innovative products aimed at improving pet health outcomes.


Top 16 Pet Medication Manufacturers Investors in the US


1. OrbiMed

  • Website: orbimed.com
  • Type: Venture Capital
  • Headquarters: New York, New York, United States (USA)
  • Founded year: 1989
  • Headcount: 51-200
  • Number of deals in 2024: 52
  • LinkedIn: orbimed-advisors

OrbiMed is a New York-based investment firm specializing in healthcare investments, founded in 1989. With approximately $17 billion in assets under management, OrbiMed operates globally and focuses on biopharmaceuticals, medical devices, and healthcare services. Notably, OrbiMed participated in a $33 million Series B2 financing round for Scout Bio, which is developing gene therapy technology for chronic diseases in pets. This investment highlights their commitment to advancing healthcare solutions for animals. Additionally, they were involved in funding Ruipeng Pet Healthcare, a major player in the pet healthcare market, which further emphasizes their interest in the pet medication sector.


2. Sosv

  • Website: sosv.com
  • Type: Venture Capital
  • Headquarters: United States (USA)
  • Founded year: 1995
  • Headcount: 51-200
  • Number of deals in 2024: 170
  • LinkedIn: sosv

SOSV is a venture capital firm founded in 1995, specializing in funding and supporting deep tech startups through its development programs. With a global reach, SOSV connects innovative companies with investors, providing venture capital investment and resources to help startups grow and succeed. Notably, SOSV has invested in several companies within the pet health sector, including AnimalBiome, which has raised funds in multiple rounds (Seed and Series A) to develop solutions for pet microbiome health. Their investment in Vetherapy also highlights their interest in pet health solutions, further establishing their relevance in the pet medication manufacturers industry.


3. Y Combinator

  • Website: ycombinator.com
  • Type: Venture Capital
  • Headquarters: San Francisco, California, United States (USA)
  • Founded year: 2005
  • Headcount: 51-200
  • Number of deals in 2024: 802
  • LinkedIn: y-combinator

Y Combinator is a prominent startup accelerator and venture capital firm based in San Francisco, California, founded in 2005. It specializes in providing funding and mentorship to early-stage technology companies through a structured program that includes resources like the Startup School and co-founder matching services. Y Combinator has successfully launched over 4,000 startups, establishing itself as a key player in the technology startup ecosystem. Notably, Y Combinator has made significant investments in the pet medication sector, including FidoCure, which raised a total of $15 million across multiple funding rounds (Seed and Series A) to develop cancer treatments for dogs. Additionally, they invested in Furmacy, a pet pharmacy, further showcasing their commitment to the pet healthcare industry. Their investment in LAIKA, a pet e-commerce platform, also highlights their broader interest in the pet industry, reinforcing their relevance as an investor in pet medication manufacturers.


4. Frazier Healthcare Partners


Frazier Healthcare Partners is a venture capital firm based in Seattle, Washington, specializing in healthcare and life sciences investments. Founded in 1991, the firm focuses on growth buyout investments in profitable healthcare businesses and innovative biopharmaceuticals. They have a strong track record of supporting companies that enhance healthcare services and products. Notably, Frazier Healthcare Partners has invested in Scout Bio, a biotechnology company that is advancing gene therapy technology for chronic diseases in pets, including diabetes and chronic kidney disease. This involvement highlights their commitment to the pet medication sector, alongside their broader healthcare investment strategy. Their portfolio also includes various other healthcare-focused companies, demonstrating their expertise and active participation in the life sciences industry.


5. Deep Tech Fund (an Alumni Ventures Fund)

  • Website: av.vc
  • Type: Venture Capital
  • Headquarters: Manchester, New Hampshire, United States (USA)
  • Founded year: 2023
  • Headcount: 51-200
  • Number of deals in 2024: 258
  • LinkedIn: deep-tech-fund-av-focused-fund

Deep Tech Fund (an Alumni Ventures Fund) is a venture capital firm based in Manchester, New Hampshire, founded in 2023. It provides accredited investors and institutions with access to professionally-managed, diversified venture portfolios. With a network of over 10,000 investors, the firm focuses on connecting them with high-quality investment opportunities in the startup ecosystem. Notably, the fund has been involved in several transactions within the pet industry, including investments in Gallant Pet, which raised funds in a Seed Round, and Nom Nom, which secured funding in a Series B round. These investments highlight the fund's engagement in the pet health and nutrition space, further emphasizing its relevance to the pet medication manufacturers sector.


6. Polaris Partners

  • Website: polarispartners.com
  • Type: Venture Capital
  • Headquarters: Boston, Massachusetts, United States (USA)
  • Founded year: 1996
  • Headcount: 11-50
  • Number of deals in 2024: 19
  • LinkedIn: polaris-partners

Polaris Partners is a venture capital firm based in Boston, Massachusetts, founded in 1996. The firm specializes in healthcare and biotechnology investments, partnering with entrepreneurs to provide funding and strategic guidance to help them innovate and grow their businesses. Polaris has a diverse portfolio that includes companies focused on transformative healthcare solutions. Notably, they have made significant investments in the pet medication sector, including Covetrus, which raised funds in a seed round, and Vets First Choice, an online veterinary partner-pharmacy that secured $4 million in financing. Additionally, they invested $10 million in FidoCure, a company dedicated to developing cancer treatments for dogs. These transactions highlight Polaris Partners' active role in supporting the pet medication industry, alongside their broader focus on healthcare.


7. IndieBio

  • Website: indiebio.co
  • Type: Venture Capital
  • Headquarters: San Francisco, California, United States (USA)
  • Founded year: 2015
  • Headcount: 1-10
  • Number of deals in 2024: 76
  • LinkedIn: indiebio

IndieBio is a venture capital firm based in San Francisco, California, founded in 2015. It specializes in biotechnology and supports startups by providing investment, mentorship, and networking opportunities to help them develop innovative solutions across various sectors, including climate and food. Notably, IndieBio has invested in companies like Vetherapy, which focuses on veterinary therapy solutions, and AnimalBiome, which works on gut health for pets. These investments highlight IndieBio's engagement in the pet health sector, showcasing their interest in advancing pet medication and health solutions. With a total of 76 investments in 2024 alone, IndieBio demonstrates a robust activity level in the biotech space, including the pet medication industry.


8. Rock Springs Capital

  • Website: rockspringscapital.com
  • Type: Venture Capital
  • Headquarters: Baltimore, Maryland, United States (USA)
  • Founded year: 2013
  • Headcount: 51-200
  • Number of deals in 2024: 16
  • LinkedIn: knectit

Rock Springs Capital is a venture capital investment firm based in Baltimore, Maryland, founded in 2013. The firm specializes in investment management and related financial services, catering to a diverse range of clients seeking asset management solutions. Notably, Rock Springs Capital has been involved in various funding rounds across different industries. One of their significant transactions includes participation in a funding round for Vets First Choice, which raised $223 million to support its international expansion in the pet medication sector. This involvement highlights their engagement in the pet medication industry, alongside other investments in pharmaceuticals and biotechnology, such as CinCor Pharma and Affinivax. Their diverse investment strategy indicates a willingness to explore opportunities in the pet health market, making them a noteworthy player in this field.


9. Michelson Impact Ventures

  • Website: michelson.vc
  • Type: Corporate
  • Headquarters: Los Angeles, California, United States (USA)
  • Founded year: 2016
  • Headcount: 1-10
  • Number of deals in 2024: 1
  • LinkedIn: michelson-impact-ventures

Michelson Impact Ventures is a social change fund based in Los Angeles, California, founded in 2016. The firm deploys impact investment capital into mission-aligned start-ups across various sectors, including education and healthcare. They support innovations through funding and accelerator programs, aiming to drive social change and improve outcomes for underserved communities. In the pet industry, Michelson Impact Ventures has made notable investments such as in AnimalBiome, which raised $595,000 in a Seed Round to enhance pet microbiome health, and Native Pet, which secured $800,000 in a Seed Round to provide natural pet food solutions. Additionally, they invested in Mixlab and Blue Pet, both of which are involved in pet health and wellness. These transactions highlight their engagement in the pet sector, particularly in areas that can impact pet health and nutrition.


10. F-Prime


F-Prime Capital is a venture capital firm based in Cambridge, Massachusetts, founded in 1946. The firm specializes in creating and investing in healthcare and technology companies, providing both venture capital investments and advisory services to entrepreneurs. F-Prime has a global presence and expertise that enables them to effectively support start-ups. Notably, they have invested in Invetx, which raised $60.5 million to develop monoclonal antibody therapeutics for chronic diseases in dogs and cats. They also participated in funding rounds for Embark Veterinary, which focuses on improving the health and lifespan of dogs. These transactions highlight F-Prime's commitment to advancing innovations in pet healthcare, making them a relevant investor in the pet medication manufacturers sector.


11. Invus

  • Website: invus.com
  • Type: Venture Capital
  • Headquarters: New York, New York, United States (USA)
  • Founded year: 1985
  • Headcount: 51-200
  • Number of deals in 2024: 35
  • LinkedIn: invus

Invus is a venture capital investment firm based in New York, specializing in equity investments and investment management since its founding in 1985. The firm partners with owner-managers across various industries to enhance business performance and create sustainable value, with a focus on long-term growth. Notably, Invus was involved in the seed round investment for Blue Buffalo in 2006, a prominent player in the pet food market that emphasizes health and wellness for pets. While their more recent transactions, such as those with Lyndra Therapeutics and Lexicon Pharmaceuticals, focus on pharmaceuticals and therapeutics, the historical investment in Blue Buffalo highlights their potential interest in the pet sector, particularly in companies that align with their investment philosophy.


12. Venrock

  • Website: venrock.com
  • Type: Venture Capital
  • Headquarters: Palo Alto, California, United States (USA)
  • Founded year: 1969
  • Headcount: 51-200
  • Number of deals in 2024: 11
  • LinkedIn: venrock

Venrock is a venture capital firm founded in 1969, based in Palo Alto, California. The firm has a strong focus on healthcare, technology, and innovation. Notably, Venrock was involved in the seed round for IDEXX Laboratories, a leading company in veterinary diagnostics and pet healthcare, which highlights their engagement in the pet medication sector. Additionally, they have invested in various healthcare companies, such as Acceleron Pharma, which, while primarily focused on human health, showcases Venrock's commitment to advancing healthcare solutions. Their diverse portfolio reflects a strategic interest in improving health outcomes across different sectors, including pet health.


13. Plug and Play Tech Center


Plug and Play Tech Center is an innovation hub and venture capital firm based in Sunnyvale, California, founded in 2006. They connect startups with corporations to foster growth and innovation, offering various programs including accelerator initiatives and investment opportunities. In the pet sector, they have been involved in notable transactions such as ImpriMed, which focuses on veterinary medicine, and Bond Pet Foods, which is developing innovative pet food products. Additionally, they have invested in Cooper Pet Care, further demonstrating their engagement in the pet industry. Their model emphasizes facilitating partnerships and providing resources to enhance business development, making them a significant player in the pet medication and care landscape.


14. GV (Google Ventures)

  • Website: gv.com
  • Type: Venture Capital
  • Headquarters: San Francisco Bay Area, California, United States (USA)
  • Founded year: 2009
  • Headcount: 51-200
  • Number of deals in 2024: 74
  • LinkedIn: gv

GV (Google Ventures) is a venture capital firm founded in 2009, based in the San Francisco Bay Area, California. With over $10 billion in assets under management, GV focuses on funding and supporting innovative technology startups across various sectors, including life sciences and artificial intelligence. Notably, GV has invested in Invetx, which raised $60.5 million in a Series B financing round to advance its monoclonal antibody pipeline for treating diseases in dogs and cats. This investment highlights GV's commitment to the pet medication industry, alongside their broader investment strategy in technology and life sciences.


15. Mars

  • Website: mars.com
  • Type: Corporate
  • Headquarters: Mclean, Virginia, United States (USA)
  • Founded year: 1935
  • Headcount: 10001+
  • Number of deals in 2024: 3
  • LinkedIn: mars

Mars, Incorporated is a leading company in the pet care, food and nutrition, and snacking industries, founded in 1935 and based in McLean, Virginia. With over 10,000 employees, Mars is dedicated to enhancing the lives of pets and consumers through quality offerings and sustainability initiatives. The company has made significant strides in the pet healthcare sector, highlighted by its acquisition of VCA Hospitals for $9.1 billion in 2017, which expanded its veterinary services. In 2023, Mars announced its agreement to acquire Heska Corporation for approximately $1.3 billion, aiming to enhance its diagnostic offerings in veterinary care. Additionally, Mars has invested in Mixlab, a modern pet pharmacy that provides personalized medication for pets, showcasing its commitment to improving pet health and medication services. These strategic moves underline Mars's active involvement in the pet medication manufacturers industry.


16. Tpg

  • Website: tpg.com
  • Type: Private Equity
  • Headquarters: San Francisco, California, United States (USA)
  • Founded year: 1992
  • Headcount: 1001-5000
  • Number of deals in 2024: 27
  • LinkedIn: tpg-capital

TPG Inc. is a leading global alternative asset manager specializing in private equity and investment management, founded in 1992 and based in San Francisco, California. The firm manages $229 billion in assets across various sectors, including technology, healthcare, and consumer markets. Notably, TPG has made significant investments in the pet healthcare sector, including the acquisition of Greencross, an Australian veterinary care company, for $675 million in 2019. This acquisition highlights TPG's commitment to the veterinary care market. Additionally, TPG has been involved in other healthcare-related investments, such as Ark Biosciences, which raised funds for its operations. These transactions demonstrate TPG's strategic insights and diversified investment opportunities in the healthcare landscape, including the pet medication manufacturers industry.



Pet Medication Manufacturers Insights: Key Investors in the US


InvestorHeadquarterSizeFoundedDeals 2024
OrbiMedNew York, New York, United States (USA)51-200198952
SosvUnited States (USA)51-2001995170
Y CombinatorSan Francisco, California, United States (USA)51-2002005802
Frazier Healthcare PartnersSeattle, Washington, United States (USA)51-200199127
Deep Tech Fund (an Alumni Ventures Fund)Manchester, New Hampshire, United States (USA)51-2002023258
Polaris PartnersBoston, Massachusetts, United States (USA)11-50199619
IndieBioSan Francisco, California, United States (USA)1-10201576
Rock Springs CapitalBaltimore, Maryland, United States (USA)51-200201316
Michelson Impact VenturesLos Angeles, California, United States (USA)1-1020161
F-PrimeCambridge, Massachusetts, United States (USA)11-50194639
InvusNew York, New York, United States (USA)51-200198535
VenrockPalo Alto, California, United States (USA)51-200196911
Plug and Play Tech CenterSunnyvale, California, United States (USA)501-10002006253
GV (Google Ventures)San Francisco Bay Area, California, United States (USA)51-200200974
MarsMclean, Virginia, United States (USA)10001+19353
TpgSan Francisco, California, United States (USA)1001-5000199227


Want to find more investors focusing on the pet medication manufacturers industry?

If you want to find more investors that are active in the pet medication manufacturersindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and there are a lot more private equity, venturecapital, and corporate investors like these globally.

With Inven, you'll also get to know:

  • Deal History: Number of deals and their sizes.
  • Portfolio: Companies they've invested in.
  • Contact data: Key dealmakers, including their emails and phonenumbers.
  • ...and much more!